✦ LIBER ✦

Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma

✍ Scribed by Robert A. Baiocchi; Lapo Alinari; Mark E. Lustberg; Thomas S. Lin; Pierluigi Porcu; Xiaobai Li; Jeffrey S. Johnston; John C. Byrd; Kristie A. Blum

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 257 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25792

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 trial of rituximab plus hyper-CV

Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma

✍ Michael Wang; Luis Fayad; Fernando Cabanillas; Fredrick Hagemeister; Peter McLau 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

## Abstract ## BACKGROUND. Relapsed or refractory mantle cell lymphoma has a very poor prognosis. The authors evaluated the response rates and survival times of patients treated with an intense regimen known to be effective against untreated aggressive mantle cell lymphoma: rituximab plus hyper‐CV

Efficacy and safety of clofarabine in re

Efficacy and safety of clofarabine in relapsed and/or refractory non-hodgkin lymphoma, including rituximab-refractory patients

✍ Chadi Nabhan; Nancy Davis; Jacob D. Bitran; Angel Galvez; Walter Fried; Kathy To 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 2 views

Phase 2 study of gemcitabine in combinat

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

✍ Yasuhiro Oki; Barbara Pro; Luis E. Fayad; Jorge Romaguera; Felipe Samaniego; Fre 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 2 views

## Abstract ## BACKGROUND. The management of recurrent or refractory Hodgkin lymphoma (HL) remains challenging. The objective of this phase 2 trial was to investigate the activity of gemcitabine in combination with rituximab in patients with recurring or refractory HL. ## METHODS. Patients were

Rituximab combined with cladribine or wi

Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma

✍ Tadeusz Robak; Piotr Smolewski; Barbara Cebula; Anna Szmigielska-Kaplon; Krzyszt 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB

Phase II trial of weekly bortezomib in c

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

✍ Irene M. Ghobrial; Wanling Xie; Swaminathan Padmanabhan; Ashraf Badros; Meghan R 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 216 KB 👁 1 views

## Abstract This study aimed to determine the activity and safety of weekly bortezomib and rituximab in patients with untreated Waldenström Macroglobulinemia (WM). Patients with no prior therapy and symptomatic disease were eligible. Patients received bortezomib IV weekly at 1.6 mg/m^2^ on days 1,

Pixantrone dimaleate in combination with

Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma : Phase 1 study with a dose-expansion cohort

✍ Tomasz P. Srokowski; James E. Liebmann; Manuel R. Modiano; Gary I. Cohen; Barbar 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB 👁 2 views

## Abstract ## BACKGROUND: Pixantrone dimaleate (pixantrone) has been shown to have antitumor activity in leukemia and lymphoma in vitro models and to lack delayed cardiotoxicity associated with mitoxantrone in animal models. FND‐R, a combination regimen of fludarabine, mitoxantrone, dexamethasone